BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 37000221)

  • 1. The novel anti-cancer fluoropyrimidine NUC-3373 is a potent inhibitor of thymidylate synthase and an effective DNA-damaging agent.
    Bré J; Dickson AL; Read OJ; Zhang Y; McKissock FG; Mullen P; Tang P; Zickuhr GM; Czekster CM; Harrison DJ
    Cancer Chemother Pharmacol; 2023 May; 91(5):401-412. PubMed ID: 37000221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I open-label, dose-escalation study of NUC-3373, a targeted thymidylate synthase inhibitor, in patients with advanced cancer (NuTide:301).
    Spiliopoulou P; Kazmi F; Aroldi F; Holmes T; Thompson D; Griffiths L; Qi C; Parkes M; Lord S; Veal GJ; Harrison DJ; Coyle VM; Graham J; Jeffry Evans TR; Blagden SP
    J Exp Clin Cancer Res; 2024 Apr; 43(1):100. PubMed ID: 38566164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Limits to thymidylate synthase and TP53 genes as predictive determinants for fluoropyrimidine sensitivity and further evidence for RNA-based toxicity as a major influence.
    Brody JR; Hucl T; Costantino CL; Eshleman JR; Gallmeier E; Zhu H; van der Heijden MS; Winter JM; Wikiewicz AK; Yeo CJ; Kern SE
    Cancer Res; 2009 Feb; 69(3):984-91. PubMed ID: 19155291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined modulation by leucovorin and alpha-2a interferon of fluoropyrimidine mediated growth inhibition.
    Sinnige HA; Timmer-Bosscha H; Peters GF; De Vries EG; Mulder NH
    Anticancer Res; 1993; 13(5A):1335-40. PubMed ID: 8239504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of FdUMP[10] in treatment of HT-29 human colon cancer xenografts.
    Liu C; Willingham M; Liu J; Gmeiner WH
    Int J Oncol; 2002 Aug; 21(2):303-8. PubMed ID: 12118325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel polypyrimidine antitumor agent FdUMP[10] induces thymineless death with topoisomerase I-DNA complexes.
    Liao ZY; Sordet O; Zhang HL; Kohlhagen G; Antony S; Gmeiner WH; Pommier Y
    Cancer Res; 2005 Jun; 65(11):4844-51. PubMed ID: 15930305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased cytotoxicity and decreased in vivo toxicity of FdUMP[10] relative to 5-FU.
    Liu J; Skradis A; Kolar C; Kolath J; Anderson J; Lawson T; Talmadge J; Gmeiner WH
    Nucleosides Nucleotides; 1999 Aug; 18(8):1789-802. PubMed ID: 10478484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of 5-fluorodeoxyuridine monophosphate-thymidylate synthase ternary complex levels by autophagy confers resistance to 5-fluorouracil.
    Nishizawa N; Kurasaka C; Ogino Y; Sato A
    FASEB Bioadv; 2023 Jan; 5(1):43-51. PubMed ID: 36643896
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thymidylate synthase inhibitors in cancer therapy: direct and indirect inhibitors.
    Rustum YM; Harstrick A; Cao S; Vanhoefer U; Yin MB; Wilke H; Seeber S
    J Clin Oncol; 1997 Jan; 15(1):389-400. PubMed ID: 8996166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Calpain regulates thymidylate synthase-5-fluoro-dUMP complex levels associated with response to 5-fluorouracil in gastric cancer cells.
    Nabeya Y; Suzuki T; Furuya A; Koide N; Ohkoshi M; Takiguchi M; Ochiai T; Matsubara H; Hiwasa T
    Cancer Sci; 2011 Aug; 102(8):1509-15. PubMed ID: 21561529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benzylacyclouridine enhances 5-fluorouracil cytotoxicity against human prostate cancer cell lines.
    Yee LK; Chu E; Pan BC; Chu SH; Chen TM; Lipsky MH; Chu MY; Calabresi P
    Pharmacology; 1998 Feb; 56(2):80-91. PubMed ID: 9494066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Positive interaction between 5-FU and FdUMP[10] in the inhibition of human colorectal tumor cell proliferation.
    Liu J; Kolath J; Anderson J; Kolar C; Lawson TA; Talmadge J; Gmeiner WH
    Antisense Nucleic Acid Drug Dev; 1999 Oct; 9(5):481-6. PubMed ID: 10555156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Time course of inhibition of thymidylate synthase in patients treated with fluorouracil and leucovorin.
    Peters GJ; van Groeningen CJ; van der Wilt CL; Meijer S; Smid K; Laurensse E; Pinedo HM
    Semin Oncol; 1992 Apr; 19(2 Suppl 3):26-35. PubMed ID: 1557655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Impact of Thymidylate Synthase and Methylenetetrahydrofolate Reductase Genotypes on Sensitivity to 5-Fluorouracil Treatment in Colorectal Cancer Cells.
    Naghibalhossaini F; Shefaghat M; Mansouri A; Jaberi H; Tatar M; Eftekhar E
    Acta Med Iran; 2017 Dec; 55(12):751-758. PubMed ID: 29373881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic exposure of colorectal cancer cells in culture to fluoropyrimidine analogs induces thymidylate synthase and suppresses p53. A molecular explanation for the mechanism of 5-FU resistance.
    Subbarayan PR; Sarkar M; Nelson G; Benitez E; Singhal S; Ardalan B
    Anticancer Res; 2010 Apr; 30(4):1149-56. PubMed ID: 20530421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unique dual targeting of thymidylate synthase and topoisomerase1 by FdUMP[10] results in high efficacy against AML and low toxicity.
    Pardee TS; Gomes E; Jennings-Gee J; Caudell D; Gmeiner WH
    Blood; 2012 Apr; 119(15):3561-70. PubMed ID: 22362039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergistic efficacy of 3n-butyrate and 5-fluorouracil in human colorectal cancer xenografts via modulation of DNA synthesis.
    Bras-Gonçalves RA; Pocard M; Formento JL; Poirson-Bichat F; De Pinieux G; Pandrea I; Arvelo F; Ronco G; Villa P; Coquelle A; Milano G; Lesuffleur T; Dutrillaux B; Poupon MF
    Gastroenterology; 2001 Mar; 120(4):874-88. PubMed ID: 11231942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dihydropyrimidine dehydrogenase but not thymidylate synthase expression is associated with resistance to 5-fluorouracil in colorectal cancer.
    Nita ME; Tominaga O; Nagawa H; Tsuruo T; Muto T
    Hepatogastroenterology; 1998; 45(24):2117-22. PubMed ID: 9951876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduction of 5-fluorouracil (5-FU) gastrointestinal (GI) toxicity resulting from the protection of thymidylate synthase (TS) in GI tissue by repeated simultaneous administration of potassium oxonate (Oxo) in rats.
    Yoshisue K; Hironaga K; Yamaguchi S; Yamamoto A; Nagayama S; Kawaguchi Y
    Cancer Chemother Pharmacol; 2000; 46(1):51-6. PubMed ID: 10912578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular Mechanisms and Tumor Biological Aspects of 5-Fluorouracil Resistance in HCT116 Human Colorectal Cancer Cells.
    Kurasaka C; Ogino Y; Sato A
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33805673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.